HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.

AuthorsJohn N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, Krish Patel, Jeff P Sharman, William G Wierda, Michael Y Choi, Susan M O'Brien, Mazyar Shadman, Matthew S Davids, John M Pagel, Habte A Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L Combs, Judith A Fox, Richard R Furman, Jennifer R Brown
JournalHaematologica (Haematologica) Vol. 107 Issue 4 Pg. 984-987 (04 01 2022) ISSN: 1592-8721 [Electronic] Italy
PMID34937320 (Publication Type: Clinical Trial, Phase I, Journal Article)
Chemical References
  • Protein Kinase Inhibitors
Topics
  • Humans
  • Neoplasms (drug therapy)
  • Protein Kinase Inhibitors (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: